Scripps Translational Science Institute
scripps.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
52
Active
19
Phase 3
0
Total enrollment
573,569
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tirzepatide | — | — | — | — | — | 1 |
Next readouts
- 2026-12
Top conditions
- Coronary Artery Disease4
- Cancer3
- Healthy3
- Hypertension3
- Prostate Cancer2
- Long COVID2
- Heart Failure2
- Atrial Fibrillation2
Frequently asked questions about Scripps Translational Science Institute
- How many clinical trials does Scripps Translational Science Institute have on ClinicalTrials.gov?
- Scripps Translational Science Institute is listed as the lead sponsor on 52 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Scripps Translational Science Institute's trials are in Phase 3?
- 0 of Scripps Translational Science Institute's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Scripps Translational Science Institute focus on?
- Scripps Translational Science Institute's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Cancer, Healthy, Hypertension, Prostate Cancer.
- When are Scripps Translational Science Institute's next clinical trial readouts?
- Scripps Translational Science Institute has 1 upcoming primary-completion readout tracked here; the soonest is “The Long COVID Treatment Trial”, expected around 2026-12.